cgen.com (CGEN): Long-Term Debt to Capital Ratio

Compugen Ltd - graphic logo of issuer CGEN

Compugen Ltd. (CGEN) business growth is driven by successful tumor antibody trials and partner payments, while the standalone long-term debt-to-equity ratio stands at 0.03. The tracked price action on the chart complements data regarding the application of AI for discovering new immunotherapy targets. Compugen Ltd. (CGEN) relies on licensing agreements with pharmaceutical leaders, favoring strategic alliances over direct acquisitions.

CGEN - Compugen Ltd Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Compugen Ltd (CGEN) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Price Compugen Limited|CGEN - Price Target Chart
- market capitalization data:
Market Capitalization Compugen Ltd.|CGEN - Enterprise Value
- book capitalization data:
Accounting Value per Share Compugen|CGEN - Company Book Value|Market-to-Book Ratio cgen.com|CGEN - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Compugen Ltd.|CGEN - Long-Term Debt to Equity|Current Liabilities to Capital Compugen Limited|CGEN - Company Aggregate Debts|Debt to Net Assets Compugen Ltd.
Fundamental company valuation:CGEN cgen.com
Brand item of Compugen

Conservative capital requires transparency in the leverage structure to assess business resilience to external shocks. This ratio correlates liabilities with a maturity of over one year against equity, determining the company's ability to finance growth without the risk of an immediate loss of liquidity. For Compugen Ltd. (CGEN) and its R&D centers in the US, this is critical, as reflected by the long-term debt-to-equity ratio.

Who Compugen Ltd. competes with

Long-Term Liabilities to Capital IBRX|Long-Term Debt to Equity Immunocore PLC IMCR|Long-Term Debt to Capital Ratio Janux Corp (JANX)|Arcus Biosciences, Inc. - Long-Term Debt to Capital|zymeworks.com - Long-Term Debt to Equity Ratio|TNGX (Tango Therapeutics, Inc.) - Long-Term Debt to Equity|IOVA: Long-Term Liabilities to Capital|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity CMPX (Compass Therapeutics)|Long-Term Liabilities to Capital replimune.com|LYEL: Long-Term Debt to Capital|Long-Term Indebtedness to Equity Innate Pharma SA IPHA|PYXS: Long-Term Debt to Equity Ratio|IOBT - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio Sutro Biopharma, Inc. (STRO)|INKT - Long-Term Debt to Capital Coefficient|werewolftx.com - Long-Term Debt to Capital|IMMX (Immix Biopharma) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity ALXO|Long-Term Debt to Equity Ratio CUE|Long-Term Debt to Equity PDSB (PDS Biotechnology)|Long-Term Debt to Equity Ratio sonnetbio.com SONN|Long-Term Debt to Equity Ratio MAIA (MAIA Biotechnology, Inc.)|Liminatus Pharma Inc. - Long-Term Debt to Capital|Lava Tx (LVTX) - Long-Term Debt to Equity|NXTC: Long-Term Debt to Capital Ratio|Long-Term Debt to Equity LPTX|Long-Term Liabilities to Capital Intensity Therapeutics, Inc.|Sensei Biotherapeutics Inc - Long-Term Debt to Equity Ratio|Long-Term Indebtedness to Equity Theriva Biologics Inc (TOVX)|Long-Term Debt to Equity Ratio Gritstone bio, Inc.|Long-Term Loans to Capital Ratio Kineta Corp (KA)|Long-Term Debt to Capital NexImmune, Inc.|Long-Term Debt to Capital Coefficient Turnstone Biologics Corp TSBX|VCNX (Vaccinex) - Long-Term Debt to Capital|HARP: Long-Term Liabilities to Capital